Tarveda Therapeutics to Present at Raymond James Life Sciences and MedTech Conference
Tarveda
Therapeutics®, Inc., a clinical stage biopharmaceutical company
discovering and developing a new class of potent and selective precision
oncology medicines for the treatment of patients with a wide range of
solid tumor malignancies, today announced that Drew Fromkin, President
and Chief Executive Officer, will present at the Raymond James Life
Sciences and MedTech Conference occurring June 18-19, 2019 in New York
City. Tarveda presentation details:
Date: Tuesday, June 18, 2019 Time: 8:00am Eastern Time Location:
Lotte New York Palace, New York, NY
About Tarveda Therapeutics®, Inc.
Tarveda Therapeutics is a clinical stage biopharmaceutical company that
is developing and discovering a new class of potent and selective
precision oncology medicines for the treatment of patients with solid
tumor malignancies. We are developing our proprietary Pentarin®
miniature conjugatesto enhance the effectiveness of promising
anti-cancer payloads by selectively binding them to desired tumor
targets where they accumulate. http://www.tarvedatx.com/
The Food is Medicine Institute at the Tufts University Friedman School of Nutrition Science and Policy convened the second annual Food is Medicine Summit this week. The Summit provided an opportunity for leaders to share advances, best practices, and...
BeiGene, Ltd. , a global oncology company, released its 2023 Responsible Business & Sustainability Report highlighting the Company's strategy, the progress it has made towards existing goals, and how it intends to achieve its bold new targets.
This...
Invensify, Inc., Santa Clara, California, has introduced a power efficient, temperature-controlled shipping container designed to maintain stable storage temperatures for high-value pharmaceuticals before and during transport to last-mile cold chain...
Oligonucleotide Synthesis Market in terms of revenue was estimated to be worth $8.8 billion in 2024 and is poised to reach $19.7 billion by 2029, growing at a CAGR of 17.5% from 2024 to 2029 according to a new report by MarketsandMarketstm.
One of...
IBM , the Government of Canada, and the Government of Quebec today announced agreements that will strengthen Canada's semiconductor industry, and further develop the assembly, testing and packaging (ATP) capabilities for semiconductor modules to be...
Blockchain technology, sustainability-focused initiatives, subscription-based business models, and digital transformation will all have a significant impact on the Loyalty Management Market in the future. Data analytics will also drive personalised...
